Colorectal Cancer Coverage from Every Angle
Advertisement
Advertisement

Heinz-Josef Lenz, MD, on Reducing Ipilimumab Dose: What Are the Ramifications?

Posted: Monday, February 3, 2020

Heinz-Josef Lenz, MD, of USC Norris Comprehensive Cancer Center, talks about whether lowering the dosage of ipilimumab affects efficacy and quality of life when treating microsatellite instability–high/DNA mismatch repair–deficient metastatic colorectal cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.
Advertisement
Advertisement